



CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Alexandria, VA 22313 on May 12, 2004

Linda Wooden

PF 114 CIP

Applicant : Jean DEREGNAUCOURT, et al.  
Serial No. : 10/805,940 Filed : March 22, 2004  
Title : Use of dextrogyral enantiomer of milnacipran for the preparation of a drug.

\* \* \* \* \*

Honorable Commissioner of Patents and Trademarks  
Alexandria, VA 22313

COMMUNICATION COVERING TRANSMITTAL OF INFORMATION  
DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

Herewith, in accord with the foregoing regulations, please find an Information Disclosure Statement which, it is respectfully submitted, should materially advance and accelerate the prosecution of the above-identified application. Attached hereto is a Form PTO-1449 and copies of the documents listed thereon. English language abstracts are provided for each foreign language document. This Information Disclosure Statement is submitted in addition to that which was filed with parent application Serial no. 10/453,574, the disclosure of which Information Disclosure Statement is incorporated by reference (copy attached hereto).

As will be noted, this Information Disclosure Statement calls a number of prior art references, which might be considered relevant, to the attention of the Office. The fact that these are in fact "Prior Art" and/or relevant to the prosecution is, however, not admitted. It is understood that, during examination, the Office will make an independent search and will identify any relevant prior art under 37 CFR § 1.104(a).

Entry of this Information Disclosure Statement into the file of this application, initialing of each reference entry, making all of the references called to the Office's attention therein of record, and favorable action on the merits of this application are all respectfully solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

By:

  
G. PATRICK SAGE

Dated: May 12, 2004  
Customer No.: 25,666  
500 Columbia Plaza  
350 East Michigan Ave.  
Kalamazoo, MI 49007  
(269) 382-0030

Enclosure: Postal Card Receipt, and  
Form PTO-1449 listing references, and copies of each reference.  
Information Disclosure Statement of US serial No. 10/453,574 filed January 19, 2004.

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR DEFECT IN THE ATTACHED CHECK, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.

PTO-1449	ATTY. DOCKET NO. PF 114 CIP	SERIAL NO. 10/805,940
LIST OF PRIOR ART CITED BY APPLICANT	APPLICANT Jean DEREGNAUCOURT, et al.	
SHEET <u>1</u> OF <u>1</u>	FILING DATE March 22, 2004	GROUP



### U.S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	6,602,911	5 AUG 03	Jay KRANZLER, et al.			
	6,635,675	21 OCT 03	Jay KRANZLER, et al.			
	10/424,212	24 APR 03	Jay KRANZLER, et al.			
	10/391,110	17 MAR 03	Srinivas RAO, et al.			

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
	03068211	21 AUG 03	WO				

### OTHER PRIOR ART

	W. RETZ, ET AL.; EUROPEAN NEUROPSYCHOPHARMACOLOGY, Vol. 5-No. 3 (1995) pages 296-297

EXAMINER	DATE CONSIDERED
<p>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	




Applicant :  
Serial No. :  
Filed :  
Title :

Jean DEREGNAUCOURT, et al.  
10/453,574  
June 3, 2003  
Use of the Dextrogyral enantiomer of  
milnacipran for the preparation of a  
pharmaceutical composition

FEB 06 2004

\* \* \* \* \*

The PTO Stamp when affixed hereon will acknowledge receipt  
by certificate of Mailing filing procedure of TRANSMITTAL OF  
INFORMATION DISCLOSURE STATEMENT Form PTO-1449 &  
copies of each reference.  
Dated: January 21, 2004  
PF 114/lw





CERTIFICATE OF MAILING  
UNC 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Alexandria, VA 22313-1450 on January 21, 2004

PF 114

\* \* \* \* \*

Applicant : Jean DEREGNAUCOURT, et al.  
Serial No. : 10/453,574  
Filed : June 3, 2003  
Title : Use of the Dextrogyral enantiomer of milnacipran for the preparation of a drug.

\* \* \* \* \*

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

COMMUNICATION COVERING TRANSMITTAL OF INFORMATION

DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

Herewith, in accord with the foregoing regulations, please find an Information Disclosure Statement which, it is respectfully submitted, should materially advance and accelerate the prosecution of the above-identified application. Attached hereto is a Form PTO-1449 and copies of the documents listed thereon. English language abstracts are provided for each foreign language document.

As will be noted, this Information Disclosure Statement calls a number of prior art references, which might be considered relevant, to the attention of the Office. The fact that these are in fact "Prior Art" and/or relevant to the prosecution is, however, not admitted. It is understood that, during examination, the Office will make an independent search and will identify any relevant prior art under 37 CFR § 1.104(a). The references consist of there references cited in the Specification and in the French Preliminary Search Report.

Entry of this Information Disclosure Statement into the file of this application, initialing of each reference entry, making all of the references called to the Office's attention therein of record, and favorable action on the merits of this application are all respectfully solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

By:   
G. PATRICK SAGE

Dated: January 19, 2004  
Customer No.: 25,666  
500 Columbia Plaza  
350 East Michigan Ave.  
Kalamazoo, MI 49007  
(616) 382-0030

Enclosure: Postal Card Receipt, and

Form PTO-1449 listing references, and copies of each reference.

\* \* \* \* \*

**THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR DEFECT IN THE ATTACHED CHECK, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.**

PTO-1449	ATTY. DOCKET NO. PF 114	SERIAL NO. 10, 3,574
LIST OF PRIOR ART CITED BY APPLICANT		
APPLICANT Jean DEREGNAUCOURT, et al.		
SHEET 1 OF 1	FILING DATE June 3, 2003	GROUP



U.S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	US 4,478,836					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
	WO0126623						
	WO0162236						
	WO9735574						
	FR2759290						
	FR2759906						

OTHER PRIOR ART

	INDEX MERCK NO. 6281
	MORET et al., 1985 NEUROPHARMACOLOGY 24(12): 1211-1219
	BONNAUD et al., 1985, Journal of Chromatography, Vol. 318: 398-403
	SHUTO et al., Tetrahedron letters, 1996 Vol. 37: 641-644
	GRARD et al., 2000, Electrophoresis 2000 21: 3028-3034
	DOYLE et al., 2001, Advanced Synthesis and Catalysis, Vol. 343. 299-302
	NORES et al., 1987 Therapie 42: 555,558
	MEADOR-WOODRUFF et al., 1988 J. Clin. Psychopharmacol. 8: 28-32
	Dictionnaire Vidal, 78 eme Edition, 2002
	The Diagnostic and Statistical Manual of Mental Disorders-IV(DSM-IV), 1995 A.P.A.
	DEPREZ et al., European Journal of Drug Metabolism & Pharmacokinetics, 1998
	SPENCER et al., DRUGS, 1998
	PUOZZO et al., European Journal of Drug Metabolism & Pharmacokinetics, 1998
	VIAZZO et al., Tetrahedron letters, 1996 vol. 37: 4519-4522
	SHUTO et al., Journal of Medicinal Chemistry, Vol. 41, Pages 3507-3514
	SHUTO et al., Journal of Med Chem, American Chem. Society, 1996, vo. 39: 4844-4852
	SHUTO et al., Japanese Journal of Pharmacology, 2001, Vol 85, pg. 207-213
	HINDMARCH I., Human Psychopharmacology 2001 UK, vol 16 pg. S101-S104
	BALDWIN D.S., Human Psychopharmacology 2001, vol 16, pg. S93-S99

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.